1. Development of mechanism-based inhibitors of mammalian/human DNA methyltransferases with IC50 values below 50 nM. The most successful inhibitors can be used for control of functional organization of mammalian genome in research laboratories, biotechnology, and ultimately in clinics for treatment of pathogenic mechanisms related to epigenetic processes (i.e. tissue regeneration, oncogenesis, psychiatric and neurological disorders, viral infections, immunological disorders).
  2. Development of novel bivalent mechanism-based inhibitors of membrane-embedded protease γ-secretase. The most successful compounds can be used for treatment and early-diagnosis of Alzheimer’s disease, or for control of different physiological processes that depend on cell-to-cell communication. Paid consultant for pharmaceutical industry, γ-secretase modulators and assays.

Career Goals

Development and commercialization of inhibitors and modulators of human DNA methyltransferase Dnmt1 and membrane embedded protease γ-secretase.

Major Accomplishments and Perspective

DNA methyltransferases

Enzymatic mechanism, regulation, and novel drug-design strategies. Present research work: Development of mechanism-based inhibitors of mammalian/human DNA methyltransferases.

Membrane-embedded protease γ-secretase

Enzymatic mechanism, regulation and novel drug-design and early diagnostic strategies for Alzheimer’s disease. Present research work: Development of novel bivalent mechanism-based inhibitors of membrane-embedded protease γ-secretase.

Substrate channeling

Substrate channeling in transient protein-protein interactions. Further research work in perspective.

Curriculum Vitae

CV in Croatian CV in English



Molecular mechanisms in epigenetics and chromatin organization; molecular mechanisms in Alzheimer’s disease; protein-protein and protein-ligand interactions; assay-development and drug-design based on enzyme structure-function principles; substrate channeling.


Enzymology: in vitro, in vivo and in silico approaches for studies of structure and function of biomolecules.


Biochemistry, physical biochemistry (i.e. biophysics), medicinal chemistry, bioorganic chemistry, molecular genetics, biological membranes, medical biochemistry, cell biology.

Work Experience

University of Rijeka Department of Biomedical Technology (2013 – present)

Position: Assistant Professor

University of Rijeka Faculty of Medicine (2010 – present)

Position: Adjunct Senior Research and Teaching Assistant

Psychiatry Hospital Rab (2010 – 2013)

Position: Supervisor of Laboratory for Medical Biochemistry

Senior Scientist Appointments

Faculty of Medicine KU Leuven Nederlands and Eli Lilly and Company Neurodegenerative Diseases Drug Hunting Team (2007 – 2010)

Project: Molecular pathophysiology of Alzheimer’s disease and inhibitors of intramembrane protease γ-secretase.
Project Leaders: Professor Bart de Strooper (KU Leuven) and Eric Karran, Ph.D. (Eli Lilly)

Washington State University School of Molecular Biosciences (2003 – 2006)

Project: DNA damage induced changes in DNA flexibility and DNA-nucleosome interaction. DNA repair in nuclear extracts.
Project Leader: Regents Professor Michael J. Smerdon

Postdoctoral Research

University of California Santa Barbara Department of Chemistry and Epigenx Pharmaceuticals, Inc. (1998 – 2000; 2002)

Project: Enzymology and inhibitors of mammalian and bacterial cytosine DNA methyltransferases.
Project Leader: Professor Norbert O. Reich

Duke University Medical Center Department of Biochemistry (2001)

Project: Enzymology of protein phosphatase CDC25B with Cdk2/CycA protein complex as the substrate (Cdk2 = cycline dependent kinase 2; CycA = cyclin A).
Project Leader: Asisstant Professor Johannes Rudolph


Oklahoma State University Department of Biochemistry and Molecular Biology (1993 – 1998)

Ph.D. Thesis Title: Substrate Channeling between NAD(H) Dehydrogenases: Enzyme Kinetics, Protein-Protein Interaction, and Molecular Modeling Studies.
Mentor: Professor H. Olin Spivey (deceased).

Max Planck Institute of Biochemistry (1992 – 1993)

Master Thesis Title: Purification of p17 protein; a component of Actin-Myosin complex from Dictyostelium discoideum.
Mentor: Emeritus Günther Gerisch

University of Zagreb Faculty of Science (1988 – 1992)

Undergraduate studies in biochemistry and molecular biology.


In Preparation

  1. Svedružić, Ž. M., Nikolić, P., Miletić, V., and Odorčić, I. Substrate-lock mechanism controls de novo methylation by mammalian DNA methyltransferase Dnmt1.
  2. Svedružić, Ž. M., Popović, K., and Šendula-Jengić, V. The basic enzymology of modulation of γ-secretase activity: identification of the key pharmacophoric groups.
  3. Svedružić, Ž. M., Svedružić, D., and Spivey, H. O. Allosteric Regulation of Substrate Channeling in Transient Protein-Protein Interactions; the case of NAD(H) dehydrogenases.
  4. Svedružić, Ž. M. A flexible loop and two charged amino acids regulate formation and break-up of transient catalytic complex between protein phosphatase CDC25B and Cdk2/Cycline-A heterodimer.



Ad hoc Reviewer

Invited Lectures (last 4 years)

  1. 248th ACS National Meeting and Exposition. ChemEpInformatics: In the Pursuit of Epidrugs Using Chemoinformatics and Computational Approaches, August 10–14, 2014, San Francisco, CA, USA. DNA methyltransferase Dnmt1: Regulation and novel drug-design strategies
  2. EuroSciCon: Alzheimer’s Drug Discovery and Development, June 25, 2014, London, UK. Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease.
  3. Ruder Bošković Institute, May 23, 2013, Zagreb, Croatia. Alzheimerova bolest iz molekularne perspektive: patogeneza, rana dijagnostika i razvoj novih lijekova.
  4. 4th Croatian Congress on Side Effects of Psychopharmacs, March 29–31 2012, Osijek, Croatia. Side effects of antipsychotics: how to avoid them and how can they be useful.

Public Talks

  1. Društvo za promociju znanosti i kritičkog mišljenja, June 13, 2014, Rijeka, Croatia. Epigenetika i utjecaj epigenetike na ljudsko ponašanje, zdravlje i budućnost medicine: prvi dio (predavanje) i drugi dio (Q&A)
  2. Psychiatric Hospital Rab, October 4–5, 2012, Rab, Croatia. Strah od znanosti i tehnologije u doba globalne ekonomske krize.

Miscellaneous Experience

  1. Conferences: almost 20 years of active participation in professional meetings and conferences.
  2. Teaching: almost 20 years of active direct and indirect mentoring of junior colleagues in research laboratories.


My sister Draženka works as a Research Scientist at NREL Bioenergy.

My name is pronounced as Zhelko Svedruzhich, with "zh" pronounced as letters "asu" in words like: "treasure", "pleasure", "measure".

My name appears on papers in different forms. Some of them are Svedruzic, ZM, Svedruzic, Z. M., Svedružić, ŽM, and Svedružić, Ž. M. Name will appear with or without Croatian accents depending on the publication.